Pharmaceuticals
Fifty percent recruitment milestone for PROPELLER prostate cancer trial
SYDNEY, Dec. 1, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that 15 of 30 participants have been recruited in the diagnostic64...
2021-12-01 21:57
2424
Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan
SHENZHEN, China, Dec. 1, 2021 /PRNewswire/ -- Shenzhen Chipscreen Biosciences' licensing partner, HUYABIO International (HUYABIO™), today announced the regulatory approval for Chidamide (Tucidinostat, also known as Epidaza ®, Hiyasta®, HBI-8000) monotherapy for the treatment of relapsed or refrac...
2021-12-01 21:54
2761
Binhai New Area to spearhead China's medical industry development
TIANJIN, China, Nov. 30, 2021 /PRNewswire/ -- Here's a news report from chinadaily.com.cn: By 2025, the Binhai New Area in North China's Tianjin municipality will cultivate industry clusters worth tens of billions of yuan that are dedicated to pharmaceuticals, biotech, medical devices, diagnosti...
2021-12-01 11:20
2322
Sai Life Sciences' pharmaceutical API manufacturing site receives Certificate of Inspection from PMDA, Japan
HYDERABAD, India, Dec. 1, 2021 /PRNewswire/ -- Sai Life Sciences, a leading
global Contract Research, Development & Manufacturing Organization
2021-12-01 09:00
3929
Silexon Partners with Excelra, Deploying GOSTAR to Strengthen its AI-driven Drug Discovery and Biopharmaceutical Research Platform
HYDERABAD, India and NANJING, China, Dec. 1, 2021 /PRNewswire/ -- Excelra, a leading global data & analytics provider, today announced its partnership with Silexon AI Technology, a next-generation biotech company with a scalable AI/ML (Artificial Intelligence and Machine Learning) platform for dr...
2021-12-01 08:05
3802
Lynk Pharmaceuticals Announced First Patient Dosed in Phase II Clinical Study of LNK01001
HANGZHOU, China, Dec. 1, 2021 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced the company has dosed the first patient with LNK01001 in its Phase II clinical trial in subjects with rheumatoid arthri...
2021-12-01 08:00
4546
Everest Medicines and Providence Therapeutics Jointly Announce Vaccine Development Strategy to Address Omicron (B.1.1.529) SARS-CoV-2 Variant
SHANGHAI and CALGARY, Canada, Dec. 1, 2021 /PRNewswire/ -- Everest Medicines and Providence Therapeutics ("Providence") jointly announced today that the companies have started working on a new version of COVID-19 vaccine specifically targeting the new Omicron variant. Scientists from the two com...
2021-12-01 08:00
3767
Innovent Biologics and Ascentage Pharma Announce the China NMPA Approval for China's First Third-Generation BCR-ABL Inhibitor Olverembatinib for the Treatment of Chronic Myeloid Leukemia
SUZHOU, China, SAN FRANCISCO and ROCKVILLE, Md., Dec. 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and...
2021-12-01 08:00
4154
Ascentage Pharma and Innovent Biologics Announce Approval for China's First Third-Generation BCR-ABL TKI Olverembatinib, Marking a Clinical Breakthrough in the Treatment of Chronic Myeloid Leukemia
SUZHOU, China and ROCKVILLE, Md., Nov. 30, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, and Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-...
2021-12-01 08:00
1996
EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants
PROVIDENCE, R.I., Dec. 1, 2021 /PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company'sEPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2 variant. EpiVax and EpiVax Therapeutics, Inc. ("EVT") are also affirming commitment to move the novel T cell epito...
2021-12-01 05:22
2683
Insilico Medicine Initiates First-in-Human Study of ISM001-055, a Novel Drug Discovered Using Insilico's Proprietary End-to-end Artificial Intelligence Platform
NEW YORK and HONG KONG, Dec. 1, 2021 /PRNewswire/ -- Insilico Medicine, an
end-to-end artificial intelligence (AI)-driven drug discovery company,today
announced that the first healthy volunteer has been dosed in a first-in-human
microdose trial of ISM001-055.
2021-12-01 05:00
4380
RedHill Biopharma Reports Operational Highlights and Third Quarter 2021 Financial Results
RedHill Accelerates its Two Advanced COVID-19 Pill Clinical Programs in Light of their Potential Against Omicron Acting independently of spike protein mutation, opaganib and RHB-107's unique host-targeted mechanisms of action hold potential versus Omicron and other variants -- Phase 2/3 study s...
2021-11-30 22:30
4930
Standigm signs MOU with Institut Pasteur Korea for AI-based drug discovery research on infectious disease
SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Standigm Inc. ("Standigm"), the leading workflow artificial intelligence (AI) drug discovery company, today announced the signing of a Memorandum of Understanding ("MOU") with Institut Pasteur Korea ("IPK"), the infectious disease-focused research...
2021-11-30 21:30
2392
Jemincare Announces the Exclusive License of the Kras Inhibitor to HUYABIO
SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- Jemincare, a leading pharmaceutical company fromChina, announced today its wholly owned subsidiary company, Shanghai Jemincare Pharmaceutical Co., Ltd., had licensed exclusive worldwide ex-China rights to the Kras inhibitor, JMKX1899, to HUYABIO Internation...
2021-11-30 20:42
4346
Treadwell Therapeutics Announces US FDA Clearance of IND Application for Phase 2 Study of TTK inhibitor, CFI-402257
NEW YORK and HONG KONG, Nov. 30, 2021 /PRNewswire/ -- Treadwell Therapeutics, a clinical stage biotechnology company developing novel therapeutics for highly aggressive cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) applic...
2021-11-30 20:00
4469
Seegene's High Multiplex PCR Assay Capable of Detecting New Omicron Variant
SEOUL, South Korea, Nov. 30, 2021 /PRNewswire/ -- Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today confirmed that its Allplex™ SARS-CoV-2 Master Assay is capable of detecting the Omicron's unique pattern of mutations. The well-established PCR-based test recogni...
2021-11-30 19:25
3338
JOYSBIO's SARS-COV-2 Antigen Rapid test detects OMICRON variant
TIANJIN, China, Nov. 30, 2021 /PRNewswire/ -- JOYSBIO, one of the world's leading manufacturers of lateral flow rapid tests, is proud to announce that their tests are available around the world. Furthermore, they've been able to show that their test can detect the new Omicron (B.1.1.529). This va...
2021-11-30 14:00
3085
ABM Therapeutics Receives IND Approval in China for BRAF Inhibitor ABM-1310
SAN DIEGO and SHANGHAI, Nov. 30, 2021 /PRNewswire/ -- ABM Therapeutics (ABM), a clinical-stage biopharmaceutical company with a focus on treating brain cancers and cancer metastases, today announced that its IND application for ABM-1310, a new-generation BRAF inhibitor, has been approved by the N...
2021-11-30 13:00
2448
Mayne Pharma and Mithra Announce TGA Approval of NEXTSTELLIS® Oral Contraceptive
ADELAIDE, Australia, Nov. 30, 2021 /PRNewswire/ -- Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce the Therapeutic Goods Administration (TGA) has approved the novel combined oral contraceptive NEXTSTELLIS® (14.2 mg of es...
2021-11-30 09:18
3686
Sciwind Biosciences Acquires Global, Exclusive Rights to Develop and Commercialize Sanofi's GIP Receptor Agonists for the Treatment of Metabolic Disease
HANGZHOU, China and SAN FRANCISCO, Nov. 30, 2021 /PRNewswire/ -- Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic disease, announced today that it has signed a global, exclusive license agreemen...
2021-11-30 08:00
3973
Week's Top Stories
Most Reposted
Visa redefines its role in travel with the global expansion of Visa Destinations
[Picked up by 336 media titles]
2026-06-30 10:00Sustainable Tourism Academy Celebrates 3,000-User Milestone in First Year with ASEAN Expansion and New Language Support
[Picked up by 323 media titles]
2026-06-29 12:41
Agoda rolls out suite of new features focused on real-time updates and smarter trip planning
[Picked up by 321 media titles]
2026-07-01 10:00
On-us Brings Real-Time Smart E-Vouchers to Google Wallet, Giving Marketers a Live Read on Customer Behavior
[Picked up by 319 media titles]
2026-06-30 11:00
Avnet Brings Ecosystem Together to Scale Edge AI in Singapore
[Picked up by 305 media titles]
2026-06-30 09:00Most Read
JINRO, the World's No. 1 Soju Brand, Partners with V of BTS
2026-07-03 08:00
6245
/UPDATE TO VIDEO -- New York Stock Exchange/
2026-07-01 01:36
5846
Farmmi, Inc. Announces Launch of Proposed Public Offering
2026-06-27 08:01
5127
NYSE Content Update: Mobility Global Marks First Day as Public Company
2026-07-01 21:22
4547
